Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Reperfusion Injury in Kidney Transplantation
NCT01756508Phase 2Completed
- Sponsor
- Russian Academy of Sciences
- Start
- Sep 2012
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in reperfusion injury (IRI), sponsored by Russian Academy of Sciences. Started Sep 2012; status: completed.
02
Drugs
eculizumab
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01756508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01756508.